Use of a Dual GIP/GLP-1 Receptor Agonist in HNF1A-MODY and HNF4A-MODY.

Autor: Broome DT; Division of Internal Medicine, Department of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI., Mehdi A; Division of Internal Medicine, Department of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI., Chase C; Department of Human Genetics, University of Michigan, Ann Arbor, MI., de Freitas MF; Division of Internal Medicine, Department of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI., Gregg BE; Division of Internal Medicine, Department of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI., Oral EA; Division of Internal Medicine, Department of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI., Herman WH; Division of Internal Medicine, Department of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI.
Jazyk: angličtina
Zdroj: Diabetes care [Diabetes Care] 2024 Sep 01; Vol. 47 (9), pp. e65-e66.
DOI: 10.2337/dc24-0730
Databáze: MEDLINE